Cite

HARVARD Citation

    Kim, H. et al. (2020). Phase I and pharmacokinetic study of the vascular‐disrupting agent CKD‐516 (NOV120401) in patients with refractory solid tumors. Pharmacology research & perspectives. 8 (2), p. n/a. [Online]. 
  
Back to record